DGAP-News: APONTIS PHARMA marks further success in the roll-out of Single Pill therapy


DGAP-News: APONTIS PHARMA AG / Key word(s): Alliance
APONTIS PHARMA marks further success in the roll-out of Single Pill therapy

12.07.2021 / 07:30
The issuer is solely responsible for the content of this announcement.

APONTIS PHARMA marks further success in the roll-out of Single Pill therapy

Monheim am Rhein, 12 July 2021.
APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pills in the German market, continues to achieve success in the roll-out of its own product portfolio.

The therapeutic effectiveness of Single Pills was verified in the study "Effect of Single pill combinations on Treatment Adherence and persistence as well as on clinical and pharmacoeconomic outcomes in the Real-world Treatment of hypertension, coronary heart disease, hyperlipidemia and in secondary prevention of cardiovascular events" (START), which was conducted in 2019. The purpose of the study, based on an anonymized health insurance data set, was to identify any differences in the forms of therapy.

Ultimately, patients benefit from a Single Pill treatment versus a multi pill regimen. Instead of taking several individual medications for a hypertension indication, taking a Single Pill that combines up to three generic active pharmaceutical ingredients provides greater adherence. Therefore, the prescribed medication is taken more reliably when the dosage form is limited to a Single Pill. Single Pill therapy for hypertensive indications has received endorsement from AXA Krankenversicherung. In a letter to the insurants, the insurance company agreed to cover the costs of the use of Single Pill and support its use.

The Single Pill therapy is evidence-based more efficient and ensures a more sustainable treatment success. The results of the START study also showed that the treatment of cardiovascular Single Pill therapy was associated with lower event rates such as stroke and myocardial infarction in German healthcare services. At the same time, fewer hospitalizations of corresponding patients were necessary. In turn, costs for health insurers are reduced and the overall therapy is less invasive.

"Cardiovascular diseases are still the most common cause of death in Germany. With AXA Krankenversicherung's support, we are raising awareness of a proven, more efficient form of Single Pill therapy and focusing our activities on around 22 million diagnosed, adult hypertensive patients in Germany alone. As a result, both patients benefit from more sustainable treatment success and health insurers from lower costs," says Karlheinz Gast, Chief Executive Officer of APONTIS PHARMA AG.


APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three generic active ingredients in a single dosage form. APONTIS PHARMA develops, promotes and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 2013, APONTIS successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europe's leading pharmaceutical and chemical region. From here, the company maintains a broad network with research-based pharmaceutical companies and a customer target group of approx. 23,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.


Investor Relations
[email protected]
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim am Rhein


Sven Pauly
Sara Pinto
[email protected]
T: +49 89 125 09 0330

12.07.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Alfred-Nobel-Str. 10
40789 Monheim
E-mail: [email protected]
Internet: https://apontis-pharma.de/
Listed: Regulated Unofficial Market in Frankfurt (Scale)
EQS News ID: 1217386

End of News DGAP News Service

1217386  12.07.2021 


Die wichtigsten Finanzdaten auf einen Blick
  2015 2016 2017 2018 2019 2020 2021e
Umsatzerlöse1 0,00 52,90 54,71 44,80 40,04 39,24 48,50
EBITDA1,2 0,00 15,68 12,40 2,81 -1,72 1,00 5,60
EBITDA-Marge3 0,00 29,64 22,66 6,27 -4,30 2,55 11,55
EBIT1,4 0,00 14,80 11,74 2,50 -2,29 -0,66 4,30
EBIT-Marge5 0,00 27,98 21,46 5,58 -5,72 -1,68 8,87
Jahresüberschuss1 0,00 14,68 11,58 2,37 -2,39 -1,18 2,60
Netto-Marge6 0,00 27,75 21,17 5,29 -5,97 -3,01 5,36
Cashflow1,7 0,00 4,24 31,09 4,46 -0,24 1,45 1,90
Ergebnis je Aktie8 0,00 1,73 1,36 0,28 -0,28 -0,14 0,31
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2020 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Ebner Stolz

Apontis Pharma
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A3CMGM 23,100 Kaufen 196,35
KGV 2022e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
48,13 0,00 0,00 94,29
4,60 135,32 5,00 163,92
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
0,00 0,00 0,00 28.04.2021
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
11.08.2021 29.04.2021
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-3,28% 0,00% 0,00% 0,00%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu APONTIS PHARMA AG  ISIN: DE000A3CMGM5 können Sie bei DGAP abrufen

Gesundheit , A3CMGM , APPH , XETR:APPH